Strategic partnerships Touchlight is actively expanding through collaborations with vaccine developers and animal health players, including SVF Vaccines and Ceva, signaling ongoing opportunities for joint development, licensing, and contract manufacturing across vaccine and biotech applications.

Cell-free DNA leadership Their patented enzymatic, cell-free dbDNA production platform positions Touchlight as a preferred supplier for genetic medicine programs (AAV, mRNA, DNA vaccines, gene editing), creating sales potential in upstream DNA synthesis, GMP manufacturing, and scale-up services.

Clinical pipeline momentum With multiple client products already in the clinic and a recent device and kit launch (EnClose Cell-free dbDNA Synthesis Kit), there are cross-sell opportunities for adjacent manufacturing services, kit-based workflows, and technical support for early-stage programs.

Regulatory credibility FDA DMF acceptance in 2022 and the world’s first cell-free DNA GMP license in 2025 demonstrate strong regulatory credibility, enabling sales pitches around quality systems, compliance, and faster regulatory-ready DNA supply for clinical programs.

Geographic and market reach Based in London with a growing global partner network and emphasis on biotechnology advancements, there is potential to pursue international biotech and pharma clients seeking innovative DNA manufacturing, as well as expansion into animal health collaborations given recent Ceva partnerships.